Abstrato

Protein heterogeneity and the immunogenicity of biotherapeutics

Roy Jefferis

Cancer and transplant patients will be receiving concomitant cytotoxic drugs that induce various levels of immunosuppression. Patients with chronic diseases that experience long term exposure to recombinant P/GPs are at greater risk but may be protected with mild immunosuppressive agents. Currently, an ever expanding armamentarium of biologics is being developed that includes engineered IgG molecules that differ in structure to endogenous IgG and/or their fragments. Such manipulations increase the propensity for immunogenicity; however, outcomes may differ between acute conditions, for which treatment may be within a relatively short time frame and chronic diseases that may require long term exposure.